- Conditions
- Rectal Adenocarcinoma, Rectal Cancer
- Interventions
- High Rare Dose Rectal Brachytherapy Boost
- Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Rochester, New York • Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1345–1368
of 3,452
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Appendix Carcinoma by AJCC V8 Stage, Colorectal Carcinoma by AJCC V8 Stage, Digestive System Neoplasm, Esophageal Carcinoma by AJCC V8 Stage, Gastric Carcinoma by AJCC V8 Stage, Liver and Intrahepatic Bile Duct Carcinoma, Peritoneal Carcinomatosis
- Interventions
- Biospecimen Collection - blood and tissue sample collection, Electronic Health Record Review
- Procedure · Other
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 2
- States / cities
- Livingston, New Jersey • New Brunswick, New Jersey
- Conditions
- Colorectal Adenocarcinoma
- Interventions
- VVD-133214, Pembrolizumab
- Drug
- Lead sponsor
- Vividion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- Tucson, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more
- Conditions
- Colon Adenocarcinoma, Rectal Adenocarcinoma, Gastric Adenocarcinoma, Pancreatic Adenocarcinoma, Hepatocellular Carcinoma, Adenocarcinoma of Biliary Tract, Gallbladder Adenocarcinoma
- Interventions
- Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Cancer of Colon
- Interventions
- Colonoscopy only, Colonoscopy outreach + mailed FIT follow-up, Colonoscopy + Mailed FIT outreach and follow-up
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 50 Years to 74 Years
- Enrollment
- 423 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Hereditary Cancer Syndrome
- Interventions
- Modified genetic counseling, Traditional genetic counseling
- Other
- Lead sponsor
- Kaiser Permanente
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 967 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Portland, Oregon
- Conditions
- Body Mass Index 25 or Greater, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Breast Carcinoma, Cancer Survivor, Chronic Lymphocytic Leukemia, Fatigue, Health Status Unknown, Lynch Syndrome, Ovarian Carcinoma, Overweight
- Interventions
- Dietary Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Questionnaire Administration, Telephone-Based Intervention
- Dietary Supplement · Other · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 337 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer, Bladder Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Breast Cancer
- Interventions
- Communication of Patients Lost to Follow-up to Providers
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 21 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 5
- States / cities
- Chicago, Illinois • Hines, Illinois • Minneapolis, Minnesota + 2 more
- Conditions
- Renal Cell Carcinoma, Colorectal Adenocarcinoma, Non-squamous Non-small Cell Lung Cancer, Platinum-refractory Ovarian Carcinoma, Cervical Carcinoma
- Interventions
- Nintedanib, Bevacizumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Malignant Melanoma, Colorectal Carcinoma
- Interventions
- PLX4032
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 5
- States / cities
- Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 2 more
- Conditions
- Advanced Cancer
- Interventions
- Brief FOCUS Program, Extensive FOCUS Program
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 484 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan • Southfield, Michigan
- Conditions
- Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Small Cell Lung Carcinoma
- Interventions
- PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV)
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 914 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 21
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Duarte, California + 13 more
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer
- Interventions
- Fitbit and Text Messages
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- IMMU-130
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colon Adenocarcinoma, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Stage I Colon Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Rectal Cancer AJCC v8, Stage II Colon Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8
- Interventions
- Biospecimen Collection, Genetic Testing, Communication Intervention, Survey Administration
- Procedure · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4,186 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2032
- U.S. locations
- 358
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 268 more
- Conditions
- Metastatic Colorectal Cancer, Hepatocellular Carcinoma
- Interventions
- Enfortumab Vedotin
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Rectal Cancer
- Interventions
- HAL proctectomy, "straight" laparoscopic proctectomy, Hand-assisted laparoscopic proctectomy, SL Proctectomy
- Procedure
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Neoplasms, Gastrointestinal Microbiome
- Interventions
- Gixam
- Device
- Lead sponsor
- Jubaan Ltd.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 426 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer, Diarrhea
- Interventions
- celecoxib, irinotecan hydrochloride
- Drug
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Breast Cancer, Colon Cancer, Lung Cancer, Lymphoma, Myeloma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Colon Cancer
- Interventions
- THUNDERBEAT, LIGASURE
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 73 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Colorectal Cancer, Metastatic Cancer
- Interventions
- carcinoembryonic antigen RNA-pulsed DC cancer vaccine
- Biological
- Lead sponsor
- Duke Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2003
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Rectal Neoplasms
- Interventions
- FOLFOX, total mesorectal excision (TME)
- Drug · Procedure
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- New York, New York
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma, Adult Diffuse Astrocytoma, Adult Ependymoblastoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Primary Hepatocellular Carcinoma, Adult Subependymoma, Advanced Adult Primary Liver Cancer, Advanced Malignant Mesothelioma, Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Adult Brain Tumor, Recurrent Adult Primary Liver Cancer, Recurrent Anal Cancer, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Bladder Cancer, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Colon Cancer, Recurrent Esophageal Cancer, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Malignant Mesothelioma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Pancreatic Cancer, Recurrent Prostate Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage II Esophageal Cancer, Stage II Pancreatic Cancer, Stage III Esophageal Cancer, Stage III Pancreatic Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Anal Cancer, Stage IV Basal Cell Carcinoma of the Lip, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Esophageal Cancer, Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Lymphoepithelioma of the Oropharynx, Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity, Stage IV Mucoepidermoid Carcinoma of the Oral Cavity, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Verrucous Carcinoma of the Larynx, Stage IV Verrucous Carcinoma of the Oral Cavity, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Unspecified Adult Solid Tumor, Protocol Specific, Untreated Metastatic Squamous Neck Cancer With Occult Primary
- Interventions
- erlotinib hydrochloride, laboratory biomarker analysis
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Chicago, Illinois